1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial
| Autor: | Oudard, S., Ratta, R., Voog, E., Barthelemy, P., Thiery-Vuillemin, A., Bennamoun, M., Hasbini, A., Aldabbagh, K., Saldana, C., Von Amsberg, G., Houede, N., Besson, D., Feyerabend, S., Boegemann, M., Falcoz, A., Vernerey, D., Belhouari, H., Kotti, S., Tran, Y., Helissey, C. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S978-S979 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|